Login / Signup
Faiez Zannad speaks to Gerhard Hindricks and Thomas F. Deering about the first randomised LAAOS Study. Double blind and high adherence to allocated arm –…
Thoughts about the use of the Win Ratio in Cardiovascular Outcome Trials
Cardiovascular trials often include non-fatal events (in addition to mortality) in their primary endpoints maintain the study power i.e., to capture enough events to detect…
Meet Spironolactone and Eplerenone’s Cardio-kidney Cousin, Finerenone
Spironolactone and eplerenone improve outcomes in heart failure. Finerenone is the newest mineralocorticoid receptor antagonist and is being tested for treatment of chronic kidney disease…
Preliminary Musings on PARADISE-MI (sacubitril-valsartan post MI)
Cardiologists have been happily prescribing angiotensin receptor neprilysin inhibitor, sacubitril-valsartan, for heart failure with reduced ejection (HFrEF) for a while now. And the drug was…
New Guidelines for Endpoints in Valve Intervention Trials: is it an autocracy?
“History has time and again shown that unlimited power in the hands of one person or group in most cases means that others are suppressed…
Colchicine and COVID-19: a Tale of Two Trials
COLCORONA was a double-blinded randomised controlled trial of over 4000 patients comparing a 30 day course of colchicine with placebo for people with COVID-19 but…
Why social media speech is not free
Many people are now noticing the harmful effects social media can have. These may range from social isolation, anxiety, depression and distortion of body image,…
CVCT Forum 2020: An Interview with Paul Armstrong about Vericiguat
Darrel Francis speaks to Paul Armstrong, PI of the VICTORIA trial, about the mechanism of new heart failure drug, Vericiguat, and the trial’s unusual power calculation: “The trial was deliberately overpowered on the primary endpoint”.
Charlie and the Medicine Factory (Do we really need to understand mechanisms?)
One of my favorite books growing up was “Charlie and the Chocolate Factory”. I revelled in the comeuppance meted out to the likes of Augustus…
CVCT Forum 2020: An Interview with Dan Mark on Patient-Reported Outcomes in Angina
At the Patient-Reported Outcome Session of CVCT Forum 2020, Dan Mark discussed the angina results of ISCHEMIA and ORBITA and the placebo effect.